GlaxoSmithKline (GSK) Pharmaceuticals Limited announced its financial results for the fourth quarter and full year ended March 31, 2025.

The company reported full year revenue of Rs. 3,723 crores, a growth of 9%. Profit After Tax before exceptional items increased by 32% to Rs. 915 crores and EBITDA margins increased by 500 basis points (bps) to 31.4%.

For the quarter ended March 31, 2025, the company reported a revenue of Rs. 966 crores, a like-to-like growth of 6%. Profit After Tax for the quarter stood at Rs.260 crores.

Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals Limited, said, “Our diversified portfolio of General Medicines, Specialty, and Vaccines has shown improved growth due to sustained innovation, enhanced Healthcare Professionals (HCP) engagement and rapid digital acceleration. This has enhanced reach, expanded coverage, and provided a seamless omnichannel experience for our customers. Our key brands, including Augmentin, Calpol, Ceftum, T-Bact, and Trelegy, have played a significant role in driving growth throughout the year. Shingrix is experiencing increased adoption, driven by heightened awareness and our efforts to develop the adult vaccination ecosystem in the country.”

“We remain committed to delivering sustained above-market growth and strong shareholder returns. In FY2025-26, we will continue to focus on our innovative portfolio through the launch of our oncology assets,” he added.

The company is on track to launch Zejula (Niraparib), a PARP inhibitor for ovarian cancer and Jemperli (Dostarlimab), an immunotherapy approved for the second-line treatment of endometrial cancer.